Arcus Biosciences Inc (RCUS)
Working capital turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 117,000 | 112,000 | 382,882 | 77,517 | 15,000 |
| Total current assets | US$ in thousands | 831,000 | 1,067,000 | 1,262,000 | 735,815 | 192,705 |
| Total current liabilities | US$ in thousands | 184,000 | 193,000 | 166,000 | 121,669 | 22,706 |
| Working capital turnover | 0.18 | 0.13 | 0.35 | 0.13 | 0.09 |
December 31, 2023 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $117,000K ÷ ($831,000K – $184,000K)
= 0.18
The working capital turnover ratio of Arcus Biosciences Inc has fluctuated over the past five years. In 2023, the working capital turnover ratio stood at 0.18, indicating that the company generated $0.18 in revenue for every dollar of working capital employed during the year. This represents an improvement compared to the previous year when the ratio was 0.13.
In 2021, the working capital turnover ratio was at its highest at 0.35, suggesting that the company efficiently utilized its working capital to generate revenue. However, in 2020 and 2019, the ratio dropped to 0.13 and 0.09 respectively, indicating a potential decline in operational efficiency during those periods.
Overall, the working capital turnover ratio of Arcus Biosciences Inc has shown variability, with fluctuations in efficiency in utilizing working capital to generate revenue over the years. Further analysis of the company's financial performance and operational activities may provide insights into the reasons behind these fluctuations.
Peer comparison
Dec 31, 2023